[Should we interfere with the interleukin-6 receptor during COVID-19: What do we know?]

Lefèvre, C; Plocque, A; Tran, M; Creux, M; Philippart, F

[Should we interfere with the interleukin-6 receptor during COVID-19: What do we know?] / Inhibiteurs du récepteur de l'IL-6 dans le traitement de la COVID-19 : que savons-nous ?

Lefèvre, C; Plocque, A; Tran, M; Creux, M; Philippart, F.

Afiliação

Lefèvre C; Medical and Surgical Intensive Care Unit, groupe hospitalier Paris Saint-Joseph, Paris, France.
Plocque A; Medical and Surgical Intensive Care Unit, groupe hospitalier Paris Saint-Joseph, Paris, France.
Tran M; Medical and Surgical Intensive Care Unit, groupe hospitalier Paris Saint-Joseph, Paris, France.
Creux M; Medical and Surgical Intensive Care Unit, groupe hospitalier Paris Saint-Joseph, Paris, France.
Philippart F; Medical and Surgical Intensive Care Unit, groupe hospitalier Paris Saint-Joseph, Paris, France; Endotoxins, Structures and Host Response, Department of Microbiology, Institute for Integrative Biology of the Cell, UMR 9891 CNRS-CEA-Paris Saclay University, 98190 Gif-sur-Yvette, France. Electronic add

Rev Mal Respir ; 40(1): 24-37, 2023 Jan.

Article em Fr | MEDLINE | ID: mdl-36577608

Assuntos

COVID-19; Síndrome do Desconforto Respiratório; Humanos; COVID-19/complicações; SARS-CoV-2; Interleucina-6; Resultado do Tratamento; Receptores de Interleucina-6

Palavras-chave

COVID 19; COVID-19; CortIcosteroid; Corticoïdes; Interleukin-6; Interleukine 6; Mortality; Mortalité; Tocilizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Síndrome do Desconforto Respiratório / COVID-19 Limite: Humans Idioma: Fr Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google